BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 2
• 3
• 4
• 5
• 8
• 9
• 10
• 11
• 12
• 15
• 16
• 17
• 18
• 19
• 21
• 22
• 23
• 24
• 25
• 26
• 29
• 30

• Drug Development

  Study Shows Novo Nordisk A/S’s New Diabetes Drug Tresiba Effective And Safe For Children

  September 16, 2014

   · 

  4 min read
• Business

  Lupin Ltd., Merck Serono Forge Emerging Markets Pact; Deal Could Add Up To 20 Drugs To Merck’s Portfolio

  September 16, 2014

   · 

  5 min read
• Policy

  Venture Backed Catheter Connections Continues to Make False Statements: Ivera Medical Corporation

  September 16, 2014

   · 

  2 min read
• Syneron Inc. Announces Details For Upcoming Investor Meeting

  September 16, 2014

   · 

  2 min read
• Genetown

  REPRISE II Data Demonstrate Sustained Safety And Performance Outcomes At One Year For The Boston Scientific Corporation Lotus™ Valve System

  September 16, 2014

   · 

  7 min read
• Drug Development

  Bayer HealthCare Pharmaceuticals And Orion Corporation Initiate Phase 3 Trial Of ODM-201 In Men With High-Risk Non-Metastatic Castration-Resistant Prostate Cancer

  September 16, 2014

   · 

  3 min read
• Drug Development

  OncoGenex Pharmaceuticals Inc. Announces Completion Of Patient Enrollment In The Phase 3 AFFINITY Trial Of Custirsen In Combination With Cabazitaxel/Prednisone As Second-Line Chemotherapy In Men With Metastatic Castrate-Resistant Prostate Cancer

  September 16, 2014

   · 

  4 min read
• Business

  PHARNEXT And The Hereditary Neuropathy Foundation Collaborate To Increase Awareness Of Charcot-Marie-Tooth Disease

  September 16, 2014

   · 

  4 min read
• Drug Development

  New Analyses Of Phase 2 Study Presented At ASBMR Show Romosozumab Treatment Resulted In Continued Increases In Bone Mineral Density

  September 16, 2014

   · 

  22 min read
• Valeant Pharmaceuticals International Announces Redemption Of All Of The Outstanding $500.0 Million Aggregate Principal Amount Of Its 6.75% Senior Notes Due 2017

  September 16, 2014

   · 

  2 min read